Discordancy in BRAF Mutations Among Primary and Metastatic Melanoma Lesions: Clinical Implications for Targeted Therapy

Modern Pathology - United Kingdom
doi 10.1038/modpathol.2014.136
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Mitochondria-Targeted Therapy for Metastatic Melanoma

English

Combining Checkpoint Inhibitors and BRAF-targeted Agents Against Metastatic Melanoma

OncoImmunology
OncologyAllergyImmunology
2013English

Rechallenge of Targeted Therapy in Metastatic Melanoma

JDDG - Journal of the German Society of Dermatology
Dermatology
2019English

Targeted Therapy and Immunotherapy: Emerging Biomarkers in Metastatic Melanoma

Pigment Cell and Melanoma Research
BiochemistryDermatologyOncologyGeneticsMolecular Biology
2020English

Uncommon BRAF Mutations Associated With Durable Response to Immunotherapy in Patients With Metastatic Melanoma

Case Reports in Oncological Medicine
Oncology
2017English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Beyond BRAF: Where Next for Melanoma Therapy?

British Journal of Cancer
Cancer ResearchOncology
2014English

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

Frontiers in Immunology
AllergyImmunology
2019English

Molecular Subtyping of Metastatic Renal Cell Carcinoma: Implications for Targeted Therapy

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy